The fourth dose of mRNA COVID-19 vaccine following 12 different three-dose regimens: Safety and immunogenicity to Omicron BA.4/BA.5

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2023, Номер unknown

Опубликована: Янв. 19, 2023

Abstract Objective To investigate the reactogenicity and immunogenicity of fourth dose using mRNA vaccines after different three-dose regimens to compare 30 µg BNT162b2 50 mRNA-1273 vaccines. Methods This prospective cohort study was conducted between June October 2022. The self-recorded evaluated on subsequent 7 days a dose. Binding neutralizing activity antibodies against Omicron BA.4/5 variants were determined. Results Overall, 292 healthy adults enrolled received or mRNA-1273. Reactogenicity mild moderate well-tolerated few days. Sixty-five individuals excluded. Thus, 227 eligible booster (n=109) (n=118). Most participants, regardless type previous three regimens, elicited significantly high level binding 28 (82.8%) (84.2%) groups comparable with median ratio 1.02. Conclusion found that can be used as for who previously immunized any prior mix match COVID-19 vaccine.

Язык: Английский

---

Pre-existing humoral immunity and CD4+ T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination

Clinical Immunology, Год журнала: 2023, Номер 251, С. 109342 - 109342

Опубликована: Апрель 24, 2023

Information regarding the heterologous prime-boost COVID vaccination has been fully elucidated. The study aimed to evaluate both humoral, cellular immunity and cross-reactivity against variants after vaccination.We recruited healthcare workers previously primed with Oxford/AstraZeneca ChAdOx1-S vaccines boosted Moderna mRNA-1273 vaccine boost immunological response. Assay used: anti-spike RBD antibody, surrogate virus neutralizing antibody interferon-γ release assay.All participants exhibited higher humoral immune response booster regardless of prior level, but those level demonstrated stronger response, especially omicron BA.1 BA.2 variants. pre-booster IFN-γ by CD4+ T cells correlates post-booster variant adjustment age gender.A mRNA is highly immunogenic. pre-existing neutralization reactivity Omicron variant.

Язык: Английский

---

Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine in children aged 5−11 years

Journal of Medical Virology, Год журнала: 2023, Номер 95(5)

Опубликована: Апрель 27, 2023

To compare the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine regimen one or two doses of inactivated followed by an in healthy children 5 11 years age, a prospective cohort study was performed at King Chulalongkorn Memorial Hospital Thailand March to June 2022. Healthy age were enrolled received (BNT162b2) (CoronaVac) BNT162b2 regimen. In addition, who BBIBP-CorV 1 3 months prior receive heterologous as third dose (booster). Reactogenicity assessed self-reported online questionnaire. Immunogenicity analysis determine binding antibodies wild-type SARS-CoV-2. Neutralizing Omicron variants (BA.2 BA.5) tested using focus reduction neutralization test. Overall, 166 eligible enrolled. Local systemic adverse events which occurred within 7 days after vaccination mild moderate well-tolerated. The BNT162b2, CoronaVac groups elicited similar levels anti-receptor-binding domain (RBD) IgG. However, higher neutralizing activities against BA.2 BA.5 variant than group. group low variant. A (booster) should be prioritized for this

Язык: Английский

---

Homologous or heterologous COVID-19 vaccine schemes: comparison of immune responses and side effects

Diagnostic Microbiology and Infectious Disease, Год журнала: 2023, Номер 107(2), С. 116017 - 116017

Опубликована: Июль 7, 2023

Язык: Английский

---

Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study

Frontiers in Immunology, Год журнала: 2023, Номер 14

Опубликована: Сен. 6, 2023

China experienced a record surge of coronavirus disease 2019 cases in December 2022, during the pandemic.We conducted randomized, parallel-controlled prospective cohort study to evaluate efficacy and antibody duration after fourth-dose booster with Ad5-nCoV or inactivated severe acute respiratory syndrome 2 (SARS-CoV-2) vaccine.A total 191 participants aged ≥18 years who had completed three-dose regimen SARS-CoV-2 vaccine 6 months earlier were recruited receive intramuscular vaccine. The group significantly higher levels compared at fourth vaccination dose. After pandemic, breakthrough infection rate for groups was 77.89% 78.13%, respectively. Survival curve analysis (p = 0.872) multivariable logistic regression 0.956) showed no statistically significant differences between two groups.Compared homologous dose, heterologous dose elicited immunogenic response healthy adults been immunized three doses Nevertheless, types equivalent pandemic.

Язык: Английский

---

Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3 to 4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2022, Номер unknown

Опубликована: Ноя. 27, 2022

Abstract Objectives Several countries have authorized a booster vaccine campaign to combat the spread of COVID-19. Data on persistence vaccine-induced immunity against new Omicron subvariants are still limited. Therefore, our study aimed determine serological immune response COVID-19 after CoronaVac-priming. Methods A total 187 CoronaVac-primed participants were enrolled and received an inactivated (BBIBP), viral vector (AZD1222) or mRNA (full-/half-dose BNT162B2, full-/half-dose mRNA-1273) as dose. The humoral both binding neutralizing antibodies wild-type was determined day 90– 120 booster. Results waning RBD immunoglobulin (Ig) levels, anti-RBD IgG, BA.1, BA.2, BA.4/5 variants observed 90–120 days vaccination. Participants who mRNA-1273 had highest immunogenicity response, followed by BNT162b2, AZD1222, BBIBP-CorV. responses between full half doses comparable. percentage reduction antibody ranged from 50% 75% among all vaccine. Conclusions substantially waned post-booster heterologous demonstrated higher detectable rate variant compared BBIBP Nevertheless, additional fourth dose is recommended maintain infection. Highlights different three platforms. Highly remained levels with half-dose can be used interchangeably full-dose mRNA-1273. activity BA.5 lower than wild type BA.2 subvariant. for individuals

Язык: Английский

---

Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax™) after homologous and heterologous two-dose regimens

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2022, Номер unknown

Опубликована: Сен. 9, 2022

Abstract Objective To report the safety and immunogenicity profile of a protein subunit vaccine (Covovax ™ ) given as third (booster) dose to individuals primed with different primary regimens. Methods Individuals two doses COVID-19 vaccines for at least 3 months were enrolled assigned five groups according their regimens: CoronaVac, BBIBP-CorV, AZD1222, BNT162b2, CoronaVac/AZD1222. Immunogenicity analysis was performed determine binding antibodies, neutralizing activity, T-cell response. Results Overall, 215 boosted Covovax vaccine. The reactogenicity achieved mild-to-moderate. Most participants elicited high level antibody responses against wild type omicron variants following booster dose. 197 classified by anti-N IgG. Of these, 141/197 (71.6%) seronegative population, activity IFN-γ release further monitored. A could elicit more than 95% 70% inhibition 28 days, respectively. cell-mediated immune Conclusion can be proposed after priming It has strong good profiles.

Язык: Английский

---

Durability of the Effectiveness of Heterologous COVID-19 Vaccine Regimens in Thailand: Retrospective Cohort Study Using National Registration Data (Preprint)

Опубликована: Апрель 17, 2023

The durability of heterologous COVID-19 vaccine effectiveness (VE) has been primarily studied in high-income countries, while evaluation policies low- and middle-income countries remains limited. We aimed to evaluate the duration during which VE regimens mitigating serious outcomes, specifically severe death following hospitalization with COVID-19, over 50%. formed a dynamic cohort by linking records Thai citizens aged ≥18 years from citizen vital, vaccine, cases registry databases between May 2021 July 2022. Encrypted identification numbers were used merge data databases. This study focuses on 8 common sequences: CoronaVac/ChAdOx1, ChAdOx1/BNT162b2, CoronaVac/CoronaVac/ChAdOx1, CoronaVac/ChAdOx1/ChAdOx1, CoronaVac/ChAdOx1/BNT162b2, BBIBP-CorV/BBIBP-CorV/BNT162b2, ChAdOx1/ChAdOx1/BNT162b2, ChAdOx1/ChAdOx1/mRNA-1273. Nonimmunized individuals considered for comparisons. was stratified according vaccination status, age, sex, province location, month vaccination, outcome. Data analysis employed logistic regression determine VE, accounting potential confounders time, observed follow-up period 7 months. includes 52,580,841 individuals, approximately 17,907,215 17,190,975 receiving 2- 3-dose vaccines (not mutually exclusive), respectively. 2-dose vaccinations offered 50% against 2 months; however, protection significantly declined time. sustained both outcomes at least months, as determined time-interaction modeling. sequence consisting CoronaVac/CoronaVac/ChAdOx1 demonstrated >80% no evidence waning. final monthly measured months after last dose 82% (95% CI 80.3%-84%) 86.3% 83.6%-84%), In Thailand, within 7-month observation period, could not maintain fatal but all did. regimen showed best protective effect COVID-19. estimated across supports adoption prime-boost strategies, primary series inactivated virus boosting either viral vector or an mRNA prevent similar pandemics countries.

Язык: Английский

---

Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated followed by an mRNA vaccine in children aged 5 - 11 years

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2022, Номер unknown

Опубликована: Ноя. 10, 2022

Abstract Objective To compare the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine regimen one or two doses of inactivated followed by an in healthy children 5-11 years age. Methods A prospective cohort study was performed at King Chulalongkorn Memorial Hospital Thailand March to June 2022. Healthy age were enrolled received (BNT162b2) (CoronaVac) BNT162b2 regimen. In addition, who BBIBP-CorV 1-3 months prior receive a heterologous as third dose (booster). Reactogenicity assessed self-reported online questionnaire. Immunogenicity analysis determine binding surrogate neutralizing antibodies SARS-CoV-2 wild-type Omicron variants. Results Overall, 166 eligible enrolled. Local systemic AE which occurred within 7 days after vaccination mild moderate well-tolerated. At one-month, post-two post-three doses, vaccinated with BNT162b2, CoronaVac/BNT162b2, elicited similar levels anti-receptor-binding domain (RBD) IgG. However, groups higher activities against BA.2 variant than CoronaVac/BNT162b2 group. Conclusion The heterologous, CoronaVac vaccine, lower emerging (booster) should be prioritized for this

Язык: Английский

---